Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Roisin E. O’Cearbhaill
ResearcherPublications, citations & collaboration network
Roisin E. O’Cearbhaill is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 412 works, 8,761 citations, an h-index of 39 and an i10-index of 111.
412
Works
8,761
Citations
39
h-index
111
i10-index
How has Roisin E. O’Cearbhaill's publication output changed over time?
ScholarIQpublication output · 2015–2024
Output grew100% over the shown period — from 1 works in 2015 to 2 in 2024.
1
1
1
2
1
2
1
2
20152016201820192020202120232024
What are the most-cited papers on Roisin E. O’Cearbhaill?
ScholarIQmost cited works
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote, René dePont Christensen, Whitney A. Spannuth Graybill, Mansoor R. Mirza, Colleen McCormick, Domenica Lorusso, Paul Hoskins, Gilles Freyer, Klaus Baumann, К. Jardon, Andrés Redondo, Richard G. Moore, Christof Vulsteke, Roisin E. O’Cearbhaill, Bente Lund, Floor Backes, Pilar Barretina-Ginesta, Ashley Haggerty, María Jesús Rubio-Pérez, Mark S. Shahin, Giorgia Mangili, William H. Bradley, Ilan Bruchim, Kaiming Sun, Izabela A. Malinowska, Yong Li, Divya Gupta, Bradley J. Monk
New England Journal of Medicine. 20192,291 CitationsOPEN ACCESS
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Ramez N. Eskander, Michael W. Sill, Lindsey Beffa, Richard G. Moore, Joanie M. Hope, Fernanda Musa, Robert S. Mannel, Mark S. Shahin, Guilherme Cantuaria, Eugenia Girda, Cara Mathews, Juraj Kavecansky, Charles A. Leath, Lilian T. Gien, Emily Hinchcliff, Shashikant Lele, Lisa M. Landrum, Floor Backes, Roisin E. O’Cearbhaill, Tareq Al Baghdadi, Emily K. Hill, Premal H. Thaker, Veena S. John, Stephen Welch, Amanda N. Fader, Matthew A. Powell, Carol Aghajanian
New England Journal of Medicine. 2023733 CitationsOPEN ACCESS
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Prasad S. Adusumilli, Marjorie G. Zauderer, Isabelle Rivière, Stephen B. Solomon, Valerie W. Rusch, Roisin E. O’Cearbhaill, Amy Zhu, Waseem Cheema, Navin K. Chintala, Elizabeth Halton, John Pineda, Rocío Pérez-Johnston, Kay See Tan, Bobby Daly, Jose A. Araujo Filho, Daniel Ngai, Erin McGee, A. Vincent, Claudia Diamonte, Jennifer L. Sauter, Shanu Modi, Devanjan Sikder, Brigitte Sénéchal, Xiuyan Wang, William D. Travis, Mithat Gönen, Charles M. Rudin, Renier J. Brentjens, David R. Jones, Michel Sadelain
Cancer Discovery. 2021578 CitationsOPEN ACCESS
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Mythili Koneru, Roisin E. O’Cearbhaill, Swati Pendharkar, David R. Spriggs, Renier J. Brentjens
Journal of Translational Medicine. 2015317 CitationsOPEN ACCESS
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer, Shannon N. Westin, Karen A. Cadoo, Geoffrey I. Shapiro, Erica L. Mayer, Roisin E. O’Cearbhaill, Robert L. Coleman, Bose Kochupurakkal, Christin Whalen, Jennifer Curtis, Sarah Farooq, Weixiu Luo, Julia Eismann, Mary K. Buss, Carol Aghajanian, Gordon B. Mills, Sangeetha Palakurthi, Paul T. Kirschmeier, Joyce F. Liu, Lewis C. Cantley, Scott H. Kaufmann, Elizabeth M. Swisher, Alan D. D’Andrea, Eric P. Winer, Gerburg M. Wulf, Ursula A. Matulonis
The Lancet Oncology. 2019262 Citations
Related on ScholarIQ
Memorial Sloan Kettering Cancer Center
Institution
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Paper
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer
Paper
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab
Paper
A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer
Paper
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
Paper